Elevance Health Inc.
HealthcareNYSE:ELV · New York Stock Exchange
+$2.93 today
Vol 0.93M · Avg 1.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.9%
avg 13.9%
ROIC
6.6%
avg 6.9%
ROA
4.7%
avg 5.2%
Analysis
ROE is currently the strongest return metric at 12.9% versus its period average of 13.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Gail Koziara Boudreaux | President, Chief Executive Officer & Director | $4.94M | — | 65 | $169,251.00 | 0.08% |
Peter David Haytaian | Special Advisor | $2.06M | — | 56 | $27,222.00 | 0.01% |
Felicia Farr Norwood | Executive VP & Chief Health Benefits Officer | $2.03M | — | 66 | $38,838.00 | 0.02% |
Mark Bradley Kaye | Executive Vice President & Chief Financial Officer | $2.01M | — | 46 | $32,037.00 | 0.01% |
Charles Morgan Kendrick Jr. | EVP and President of Commercial & Specialty Health Benefits | $1.91M | — | 60 | $11,791.00 | <0.01% |
Kyle Weber | Chief Strategy Officer & Interim Chief Marketing Officer | — | — | — | — | — |
Nathan Allen Rich | Vice President of Investor Relations | — | — | — | — | — |
Ronald William Penczek | Senior Vice President, Controller & Chief Accounting Officer | — | — | 61 | $4,109.00 | <0.01% |
Scott Wayne Anglin | SVP, Treasurer & Chief Investment Officer | — | — | — | — | — |
Erin Wessling | Executive VP & Chief Legal Officer | — | — | 48 | $7,579.00 | <0.01% |
Julie Goon | Senior Vice President of Public Affairs | — | — | — | $31,213.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$3.68M
Sells
3
$1.54M
Net Sentiment
+$2.15M
Net buying
Most Active
BOUDREAUX GAIL
3 transactions
Analysis
Insiders reported 5 buys worth $3.68M and 3 sells worth $1.54M over the last 12 months. That adds up to net buying of $2.15M. BOUDREAUX GAIL was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +4.7% | +11.3% (15yr)1 analysts |
| Revenue | N/A | N/A | +8.8% | +7.6% (15yr)6 analysts |
| Net Income | N/A | N/A | -1.2% | +9.7% (15yr)6 analysts |
| EBIT | N/A | N/A | +6.7% | +5.7% (15yr)6 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.8% over three years. Forward estimates point to EPS at +11.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.97B
GSK plc
NYSE:GSK
$106.56B
Cigna Corporation
NYSE:CI
$78.80B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.29B
Cencora, Inc.
NYSE:COR
$54.88B
Becton, Dickinson and Company
NYSE:BDX
$52.85B
Humana Inc.
NYSE:HUM
$45.43B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.09B
Zoetis Inc.
NYSE:ZTS
$33.64B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.58B
Who manages ELV?
Elevance Health Inc. (ELV) lists 11 active executives. The top listed executive is Charles Morgan Kendrick Jr., EVP and President of Commercial & Specialty Health Benefits.
Are ELV insiders buying or selling?
Recent insider activity shows net buying of $52.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.